A generative-AI-designed drug candidate cleared a randomized Phase IIa trial with measurable efficacy, concrete evidence that AI-driven target and molecule design can produce clinically active compounds, not just faster screening.

• articleAI-designed rentosertib lowers predicted biological age across six proteomic clocksInsilico Medicine
• postAn agent generated a cancer hypothesis, and the lab confirmed itAi2
• article🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai DiscoveryRJ Honicky

Checking sign-in…

Loading comments…